ARROWHEAD PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
ARWR$49.24-15.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except per share amounts)
| June 30, 2024 | September 30, 2023 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and restricted cash | $69,399 | $110,891 |
| Available-for-sale securities, at fair value | 367,272 | 292,735 |
| Prepaid expenses | 9,207 | 8,813 |
| Other current assets | 4,184 | 4,033 |
| Total current assets | 450,062 | 416,472 |
| Property, plant and equipment, net | 375,911 | 290,262 |
| Intangible assets, net | 8,987 | 10,262 |
| Right-of-use assets | 44,339 | 45,297 |
| Other assets | 4,460 | 3,259 |
| Total Assets | $883,759 | $765,552 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $26,550 | $35,866 |
| Accrued expenses | 47,899 | 39,763 |
| Accrued payroll and benefits | 15,795 | 17,963 |
| Lease liabilities | 6,053 | 10,563 |
| Deferred revenue | — | 866 |
| Other liabilities | 417 | 435 |
| Total current liabilities | 96,714 | 105,456 |
| Long-term liabilities: | ||
| Lease liabilities, net of current portion | 112,040 | 104,608 |
| Liability related to the sale of future royalties | 336,031 | 268,326 |
| Total long-term liabilities | 448,071 | 372,934 |
| Commitments and contingencies (Note 7) | ||
| Noncontrolling interest and stockholders’ equity: | ||
| Common stock, $0.001 par value:Authorized 290,000 shares; issued and outstanding 124,227 and 107,312 shares | 217 | 200 |
| Additional paid-in capital | 1,786,304 | 1,300,395 |
| Accumulated other comprehensive loss | (987) | (3,222) |
| Accumulated deficit | (1,454,987) | (1,026,030) |
| Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity | 330,547 | 271,343 |
| Noncontrolling interest | 8,427 | 15,819 |
| Total noncontrolling interest and stockholders’ equity | 338,974 | 287,162 |
| Total Liabilities, Noncontrolling Interest and Stockholders’ Equity | $883,759 | $765,552 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.